Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | RINGSIDE: Phase II/III trial of AL102 for the treatment of desmoid tumors

Robin Jones, MBBS, MRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK, discusses results from part A of the Phase II/III RINGSIDE (NCT04871282) investigating 3 doses of the gamma secretase inhibitor, AL102, in desmoid tumors. Phase II is open-label with safety as the primary endpoint. Phase III is a double-blind, placebo-controlled study with progression-free survival (PFS) as the primary endpoint. 30 patients with progressive desmoid tumors were enrolled into Phase II. There were no deaths or life-threatening treatment-related adverse events (TREAEs). The most common AEs were diarrhea, rash, nausea, fatigue and stomatitis. In terms of efficacy, early volume and RECIST responses were observed in all 3 dose arms at week 16. Prof. Jones also discusses further efficacy responses. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.